As popular GLP-1 weight-loss medications continue to transform obesity treatment, doctors and researchers are grappling with an unexpected drawback: patients frequently lose significant amounts of muscle alongside body fat. To tackle this problem, pharmaceutical companies are now testing experimental muscle-boosting drugs designed to preserve lean muscle mass during weight loss.
The foundation for these muscle-building treatments goes back to the 1990s, when researchers discovered a protein named myostatin that acts as a natural brake on muscle growth. Genetically blocking myostatin in laboratory mice resulted in remarkably muscular animals. Similar genetic variations were later identified in unusually muscular breeds of cattle, dogs, and even rare human cases, suggesting that inhibiting myostatin could boost human muscle mass.
However, developing effective treatments for humans has turned out to be far more complex than in animal models. Human muscle regulation involves multiple factors that can cause muscle loss, including a related protein called activin A that binds to the same cellular receptors as myostatin. While mice experienced dramatic muscle growth when myostatin was blocked alone, human participants in early trials saw maximum muscle increases of only about 10 percent. Furthermore, early candidate drugs triggered unwanted side effects because they interfered with related growth factors involved in processes such as blood clotting.
The massive surge in GLP-1 usage has revitalized research into muscle preservation. When individuals discontinue GLP-1 treatments, they tend to regain fat quickly without regaining lost muscle at the same pace, raising concerns about long-term frailty and metabolic health. In response, scientists are trialing combination therapies that pair GLP-1 drugs with antibodies targeting myostatin and activin A.
Early animal studies yielded promising results, with monkeys gaining lean muscle while losing more weight than those given GLP-1 drugs alone. However, interim results from human phase II clinical trials highlight lingering challenges. Although a triple-drug combination successfully prevented 80 percent of the muscle loss caused by semaglutide, roughly one-third of human trial participants suffered side effects severe enough to discontinue the trial. Researchers are now working to refine these therapies to achieve a safer balance between losing weight and staying strong.